Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2b study evaluating the efficacy, safety and tolerability of APEX-52, a microdose, orally administered synthetic psilocybin drug product in treating depression and anxiety among adults diagnosed with PTSD

Next Previous
Search
Trial Profile

A phase 2b study evaluating the efficacy, safety and tolerability of APEX-52, a microdose, orally administered synthetic psilocybin drug product in treating depression and anxiety among adults diagnosed with PTSD

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Psilocybin (Primary)
  • Indications Anxiety; Depression
  • Focus Therapeutic Use
  • Acronyms PATHFINDER-52

    • Most Recent Events

    • 24 Jan 2023 New trial record
    • 19 Jan 2023 According to an Apex Laboratories media release, recruitment in the trial will begin in the first half of 2023 and the trial will take place over the course of three months.
    • 19 Jan 2023 According to an Apex Laboratories media release, the trial will be conducted at Centricity Research. Trial sites will be located in Ontario and Atlantic Canada.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top